EGFR expression in colon cancer: A break in the clouds [2]

Annals of Oncology

Volumn 17, Issue 12, 2006, Pages 1850-1851

  Etienne Grimaldi, M C ^a   Cayre, A ^b   Penault Llorca, F ^b   Francoual, M ^a   Formento, J L ^a   Benchimol, D ^c   Bourgeon, A ^c   Milano, Gerard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b CENTRE JEAN PERRIN   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; LIGAND; TYROSINE KINASE RECEPTOR;

BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CANCER STAGING; CELL ACTIVATION; CELL CLONE; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; LETTER; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SIGNAL TRANSDUCTION;

BINDING SITES; COLONIC NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33845350440     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl138     Document Type: Letter

References (11)

1. Khamly K, Jefford M, Michael M et al. Beyond 5-fluorouracil: New horizons in systemic therapy for advanced colorectal cancer. Expert Opin Investig Drugs 2005; 14: 607-628.
2. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
3. Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer 2005; 5: 19-27.
4. Cunningham MP, Essapen S, Thomas H et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 2005; 27: 317-325.
5. Francoual M, Etienne-Grimaldi MC, Formento JL et al. EGFR in colorectal cancer: More than a simple receptor. Ann Oncol 2006; 17: 962-967.
6. Defize LH, Boonstra J, Meisenhelder J et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989; 109: 2495-2507.
7. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
8. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
9. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
10. Penault-Llorca F, Cayre A, Arnould A et al. Comparison of three commercially available immunohistochemical tests for EGFR expression in colorectal cancers. Is immunohistochemistry reliable? Laboratory Investigation 2006; 86: 116A-117A.
11. Formento JL, Francoual M, Formento P et al. Epidermal growth factor receptor assay: Validation of a single point method and application to breast cancer. Breast Cancer Res Treat 1990; 17: 211-219.